Advertisement / Advertisement
InnoCan Pharma* (WKN: A2PSPW) provides what I consider to be groundbreaking proof of the therapeutic viability of its LPD technology in combating inflammatory diseases of the central nervous system.
InnoCan Pharma* (NYSE:InnoCan Pharma*) (NYSE:CNA) is a Canadian-Israeli pharmaceutical company that is at the forefront of developing new CBD-based solutions to treat cellular damage in the central nervous system (CNS). Founded and led by some of the biotech and pharma-tech industry giants, InnoCan has strategic partnerships with some of Israel's most prestigious research institutions, enabling the company to develop innovative products, including its signature exosome and liposome delivery systems, which introduce a new... mechanism that injects CBD into the bloodstream more efficiently than current oral methods (source: Yahoo Finance).
The company recently announced financing at a price of CAD 0.85. Now, only five days later, it was already "closed" (Link)
InnoCan Pharma* (WKN: A2PSPW) has a lot to offer for the funds now invested, because the research areas are in a sector that couldn't be more interesting. Combating central nervous system disorders, which often prove incurable, is ultimately a multi-billion dollar market that greedily awaits any remedy that promises relief. Today they release more data on the LPT (CBD embedded in liposomes) delivery method which, to my mind, couldn't be more sensational to say the least:
Innocan Reports of Presence of CBD in Mice's Brains 41 Days After Injection of CBD Using Innocan's Liposome Platform Technology
InnoCan Pharma* (NYSE:IBD) announces new study results on its LPT (CBD embedded in liposomes) technology, conducted by Prof. Chezy Barenholz of the Hebrew University of Jerusalem. These state that CBD could still be detected in the brains of mice after 41 days, in contrast to zero CBD 22 days after a conventional injection.
*Please note the following information on the conflicts of interest definitely existing at bullVestor with regard to this publication as well as our risk information and our disclaimer
Subscribe to my free newsletter
Risk Warning and Disclaimer
We expressly point out that we assume no liability for the content of external links. Every investment in securities involves risks. Political, economic or other changes can lead to significant price losses. This applies in particular to investments in (foreign) second-line stocks and in small and microcap companies. Due to the low market capitalization, investments in such securities are highly speculative and involve a high risk, up to and including the total loss of the invested capital. In addition, some of the stocks presented at bullVestor are subject to currency risks.
The background information and market assessments published by bullVestor for the German-speaking area were created in compliance with the Austrian and German capital market regulations and are therefore intended exclusively for capital market participants in the Republic of Austria and the Federal Republic of Germany. Other foreign capital market regulations were not taken into account and do not apply in any way. BullVestor's publications are for informational purposes only and expressly do not represent a financial analysis, but are promotional texts of a purely advertising nature for the companies discussed, which pay a fee for this.
No consulting contract comes about between the reader and the authors or the publisher through the purchase of the bullVestor publications. All information and analyzes do not represent an invitation, offer or recommendation to buy or sell investment instruments or for other transactions. Every investment in shares, bonds, options or other financial products is associated with risks, some of which are considerable.
The editors and authors of the bullVestor publications are not professional investment advisors. It is therefore essential that you always seek advice from a qualified specialist (e.g. your house bank or a qualified advisor you trust) when making your investment decisions. All information and data published by bullVestor comes from sources that we believe to be reliable and trustworthy at the time of writing. However, no guarantee can be given with regard to the correctness and completeness of this information and data.
The same applies to the evaluations and statements contained in bullVestor's analyzes and market assessments. These were created with the necessary care. Any responsibility or liability for the correctness and completeness of the information contained in this publication is excluded. All statements of opinion made reflect the current assessment of the authors, which can change at any time without prior notice. There is expressly no guarantee or liability that the price or profit developments forecast in the bullVestor publications will occur.
Information on conflicts of interest
The publisher and responsible authors hereby declare that the following conflicts of interest exist with regard to the company discussed in this publication at the time of publication:
Imprint:
bullVestor Medien GmbHGutenhofen 44300 St. Valentin AustriaTel: +43 7435 54077-0 Company registration number: FN275279yManaging director and 100% owner: Helmut PollingerPlace of jurisdiction: St. Pöltenkontakt[at]bullvestor.at- advertisement -
Values included: CA45783P1027
